Elevated urinary monocyte chemoattractant protein-1 levels in children with Henoch-Schonlein purpura nephritis

Chemokine monocyte chemoattractant protein-1 (MCP-1) has been proved as a potential urinary biomarker in nephropathies. The aim of this study was to investigate the urinary monocyte chemoattractant protein-1 (MCP-1) levels and clinical significance in Henoch-Schonlein purpura (HSP) children with and without nephritis and determine the association of MCP-1 with proteinuria.
Source: Pediatrics and Neonatology - Category: Perinatology & Neonatology Authors: Tags: Original Article Source Type: research

Related Links:

ConclusionM is more common in IgAN. HSPN had more S than IgAN over the course of more than 12  months. These results indicate the differences in the pathogenesis in IgAN and HSPN. We propose early biopsy and active treatment of HSPN within 12 months to delay the development of chronic lesions.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
This study was performed to evaluate the curative effect and safety of a traditional Chinese me dicine (TCM) integrated treatment program in this type of HSPN.MethodsThis multicenter, open-label, large-sample, randomized controlled trial was performed in China and included 500 children with HSPN exhibiting mild pathological patterns. The treatment group to control group ratio was 2:1, and each group was further stratified into two types, light and heavy, according to urinary protein quantification and pathological type. The treatment group received tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, a...
Source: Trials - Category: Research Source Type: clinical trials
ConclusionsLong-term outcome was relatively good in both treatment groups. However, since urinary abnormalities may persist or develop, long-term follow-up of HSN patients is mandatory. Early initiation of treatment had a favorable effect on proteinuria.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionAdministration of immunosuppressive agents combined with steroids may be a superior alternative for HSPN. Nevertheless, long-term, high-quality, large-sample, and  multicenter RCTs are required to make the results more convincing.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionThe long-term morbidity of HSP is predominantly attributed to renal involvement. Patients with HSP, who have a high risk to develop nephritis, could be followed for longer periods of time. The Oxford classification is useful in predicting long-term outcomes of HSPN.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
Conclusion: We analyzed and summarized the clinical characteristics of patients with HSPN and found that dampness-heat accumulation was dominant in patients and was always accompanied by immune disorders and coagulation disorders. These results provided the largest therapeutic effects of Chinese herbs decoction for clinical treatment. PMID: 29849695 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Correlation between serum inflammatory factors TNF-α, IL-8, IL-10 and Henoch-Schonlein purpura with renal function impairment. Exp Ther Med. 2018 Apr;15(4):3924-3928 Authors: Yuan L, Wang Q, Zhang S, Zhang L Abstract The changes of tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), interleukin-10 (IL-10) in the serum of Henoch-Schonlein purpura nephritis (HSPN) patients were analyzed to explore the correlation between the above inflammatory factors and progression of the disease. The present study used the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method t...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionOur study demonstrates that MMF is a safe and potentially effective secondary treatment option for children with HSPN to achieve and maintain long-term remission without serious side effects. To achieve complete remission within 3  months, resolve severe inflammatory glomerular lesions, and avoid progression to chronic kidney disease, we propose timely diagnosis and early initiation of MMF with an eMPA-AUC0 –12h value of 56.4 mg*h/l.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
This study correlates the clinical presentation of Henoch –Schönlein purpura nephritis (HSPN) with findings on initial renal biopsy.MethodsData from 202 pediatric patients enrolled in the HSPN registry of the German Society of Pediatric Nephrology reported by 26 centers between 2008 and 2014 were analyzed. All biopsy reports were re-evaluated for the presence of cellular crescents or chronic pathological lesions (fibrous crescents, glomerular sclerosis, tubular atrophy>5%, and interstitial fibrosis>5%).ResultsPatients with HSPN with cellular glomerular crescents were biopsied earlier after onset of nephrit...
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
The objective of this study was to evaluate prevalence, initial risk factors, and outcomes in Henoch-Sch önlein purpura nephritis (HSPN) patients in Latin America. Two hundred ninety-six patients (validated EULAR/PRINTO/PRES HSP criteria) were assessed by demographic data, clinical/laboratorial involvements, and treatments in the first 3 months after diagnosis. They were followed-up in a Latin Americ an tertiary center and were divided in two groups: with and without nephritis. Persistent non-nephrotic proteinuria, nephrotic proteinuria, and acute/chronic kidney injury were also systematically evaluated at 1, 5, ...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Children | Henoch-Schonlein Purpura | Men | Nephritis | Pediatrics | Proteinuria | Study